Kabra Drugs Current Share Price | Kabra Drugs Stock Screener
KABRADG
Pharmaceuticals
Kabra Drugs Current Stock Price Today
Live Share Price BSE
₹19.08
▼
-0.14 (-0.73%)
As of September 18, 2026, the live Kabra Drugs share price (BSE: KABRADG) is ₹19.08, down 0.73% from the previous close, with shares trading between ₹18.80 and ₹19.83 in today's trading session, and a 52-week range of ₹15.97–₹34.67.
Browse KABRADG balance sheet details to support your investment research.
Use the Kabra Drugs stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Kabra Drugs Market Cap
₹49.32 Cr.
KABRADG P/E Ratio (TTM)
6.29
Kabra Drugs P/B Ratio
1.61
EPS (TTM)
₹2.09
Dividend Yield
-
Debt to Equity
0.08
KABRADG 52 Week High
₹34.67
Kabra Drugs 52 Week Low
₹15.97
Operating Margin
7.00%
Profit Margin
6.06%
KABRADG Revenue (TTM)
₹132.00
EBITDA
₹9.00
Net Income
₹8.00
Total Assets
₹86.00
Total Equity
₹30.00
Kabra Drugs Current Share Price Chart
Track the current Kabra Drugs share price and stock price with an interactive chart. Analyse KABRADG price trends, trading volume, historical performance, and volatility across different timeframes — the complete Kabra Drugs stock quote in one place.
Kabra Drugs Company Profile - Fundamental Screener
Screen Kabra Drugs company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for KABRADG shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE323K01017
Kabra Drugs Balance Sheet Screener
Screen KABRADG balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 86 | 25 | 5 | 1 | 1 | 1 | 1 | 2 | 2 | 6 |
| Current Assets | 84 | 25 | 5 | 1 | 1 | 1 | 1 | 1 | 2 | 4 |
| Fixed Assets | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 30 | 25 | 1 | -1 | 0 | 0 | 0 | 0 | 0 | 3 |
| Share Capital | 24 | 24 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| Reserves & Surplus | 6 | 1 | -6 | -5 | -5 | -5 | -4 | -4 | -4 | -2 |
Kabra Drugs Income Statement Screener - Profit & Revenue Analysis
Screen Kabra Drugs income statement and profit fundamentals.
Analyze KABRADG quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Kabra Drugs share price evaluation.
| Item | None-None | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 132 | 93 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 8 | 10 | 8 |
| Expenses | 123 | 87 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 3 | 7 | 9 | 8 |
| EBITDA | 9 | 5 | -1 | -1 | 0 | 0 | 0 | 0 | 0 | -1 | 1 | 1 | 0 |
| Operating Profit % | 7.00% | 6.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -57.00% | 6.00% | 5.00% | 5.00% |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 9 | 6 | -1 | -1 | 0 | 0 | 0 | 0 | 0 | -2 | 0 | 0 | 0 |
| Tax | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | 8 | 5 | -1 | -1 | 0 | 0 | 0 | 0 | 0 | -2 | 0 | 0 | 0 |
| EPS | 3.20 | 2.09 | -0.99 | -1.68 | -0.77 | -0.42 | -0.41 | -0.14 | -0.38 | -5.37 | 0.30 | 0.06 | 0.16 |
Kabra Drugs Cash Flow Screener - Liquidity Fundamentals
Screen KABRADG cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | -5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investing Activities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| Financing Activities | 23 | 3 | 0 | 0 | 0 | 0 | 0 | -1 | 0 | 0 |
| Net Cash Flow | 19 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Kabra Drugs Shareholding Pattern Screener
See Kabra Drugs shareholding pattern with promoter, FII, and DII holdings.
Check Kabra Drugs promoter holding and ownership changes for KABRADG on TickJournal.
| Item | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 90.92% | 90.69% | 95.94% | 95.61% | 95.00% | 91.43% | 95.73% | 95.85% |
| Other Holding | 9.08% | 9.31% | 4.06% | 4.39% | 5.00% | 8.57% | 4.27% | 4.15% |
| Shareholder Count | 9,185 | 9,680 | 7,435 | 7,449 | 8,098 | 8,862 | 7,364 | 7,336 |
Kabra Drugs Share Dividend Screener - Share Yield Analysis
Check Kabra Drugs dividend history with payout and yield data.
View Kabra Drugs dividend details including ex-dates and amounts for KABRADG stock.
Kabra Drugs Stock Index Membership
See which indices include Kabra Drugs stock.
Check KABRADG index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Kabra Drugs Market Events Screener - Corporate Actions
Get Kabra Drugs corporate actions including splits, bonuses, and buybacks.
Check Kabra Drugs stock events that may affect KABRADG share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-09-30 | 2026-09-30 | Annual General Meeting | NA | 5.09% |
| 2026-08-12 | 2026-08-12 | Quarterly Result Announcement | NA | -1.50% |
| 2026-05-29 | 2026-05-29 | Quarterly Result Announcement | NA | 0.36% |
| 2026-02-13 | 2026-02-13 | Quarterly Result Announcement | NA | 11.26% |
| 2025-12-26 | 2025-12-26 | Extraordinary General Meeting | NA | -0.91% |
| 2025-11-13 | 2025-11-13 | Quarterly Result Announcement | NA | 7.48% |
| 2025-09-30 | 2025-09-30 | Annual General Meeting | NA | -1.53% |
| 2025-08-14 | 2025-08-14 | Quarterly Result Announcement | NA | 1.97% |
| 2025-05-30 | 2025-05-30 | Quarterly Result Announcement | NA | 0.00% |
| 2025-02-14 | 2025-02-14 | Quarterly Result Announcement | NA | 4.97% |
| 2025-01-02 | 2025-01-02 | Extraordinary General Meeting | NA | 4.90% |
| 2024-11-14 | 2024-11-14 | Quarterly Result Announcement | NA | 4.92% |
| 2024-09-30 | 2024-09-30 | Annual General Meeting | NA | 4.94% |
| 2024-02-17 | 2024-02-17 | Extraordinary General Meeting | NA | 10.13% |
| 2020-09-02 | 2020-09-02 | Change Of Name | NA | 0.00% |
Kabra Drugs Competitors Screener - Peer Comparison
Screen KABRADG competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 441,478 | 36.91 | 61,674 | 12.69% | 11,565 | 34.00 |
| Divis Laboratories | 247,470 | 85.36 | 11,067 | 13.95% | 2,568 | 63.65 |
| Torrent Pharmaceuticals | 188,872 | 86.95 | 13,886 | 20.34% | 2,138 | 52.16 |
| Zydus Life Science | 112,608 | 24.28 | 27,658 | 17.64% | 5,026 | 45.64 |
| Cipla | 110,352 | 33.22 | 29,045 | 2.24% | 3,870 | 35.27 |
| Laurus Labs | 106,298 | 95.94 | 6,868 | 22.01% | 890 | 68.28 |
| Dr Reddys Laboratories | 97,281 | 29.91 | 35,059 | 3.90% | 4,158 | 47.72 |
| Aurobindo Pharma | 96,652 | 25.88 | 34,145 | 5.56% | 3,503 | 57.04 |
| Lupin | 95,790 | 17.09 | 29,039 | 26.75% | 5,356 | 28.17 |
| Mankind Pharma | 94,163 | 44.87 | 14,636 | 14.85% | 1,938 | 37.57 |
Kabra Drugs Company Announcements - News Screener
Screen KABRADG latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-09-16 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-09-15 | Reg. 34 (1) Annual Report. | - |
| 2026-09-14 | Submission Of Notice Of Annual General Meeting Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligation And Disclosure Requirements) Regulations 2015 | - |
| 2026-09-10 | Book Closure And Schedule Of Events For E-Voting. | - |
| 2026-09-02 | Appointment Of Internal Auditor Of The Company | - |
| 2026-09-02 | Appointment Of Secretarial Auditor Of The Company | - |
| 2026-09-02 | Board Meeting Outcome for Outcome Of Board Meeting Held On 02Nd September 2026 | - |
| 2026-08-29 | Announcement under Regulation 30 (LODR)-Change in Registered Office Address | - |
| 2026-08-27 | Board Meeting Intimation for Intimation Of Board Meeting To Be Held On 02Nd September 2026 | - |
| 2026-08-18 | Reconstitution Of The Composition Of The Board & Committees Of Regulation 30 Of SEBI (LODR) Regulations 2015 | - |
| 2026-08-18 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-12 | Announcement under Regulation 30 (LODR)-Resignation of Director | - |
| 2026-08-12 | Undertaking For Non- Applicability Of Regulation 32 Of SEBI | - |
| 2026-08-12 | Financial Results For The Quarter Ended 30Th June 2026 | - |
| 2026-08-12 | Board Meeting Outcome for Outcome Of Board Meeting Held On 12Th August 2026 | - |
| 2026-08-05 | Board Meeting Intimation for Intimation Of Board Meeting To Be Held On 12-August-2026 | - |
| 2026-07-09 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-07-07 | Announcement under Regulation 30 (LODR)-Change of Company Name | - |
| 2026-06-26 | Closure of Trading Window | - |
| 2026-06-14 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |